Skip to search formSkip to main contentSkip to account menu

cabazitaxel

Known as: 1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate], 4-acetoxy-13-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate, Cabazitaxelum 
A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes… 
National Institutes of Health

Related topics

Related topics

10 relations
1.5 ML cabazitaxel 40 MG/ML Injection1.5 ML cabazitaxel 40 MG/ML Injection [Jevtana]ApoptosisMicrotubule Process

Narrower (3)

JevtanaTXD 258XRP6258

Broader (1)

Taxoids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Key Points Question How is sipuleucel-T being used to treat patients with advanced prostate cancer, and what are the factors… 
2019
2019
The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma
Paclitaxel is highly effective at killing many malignant tumors; however, the development of drug resistance is common in… 
Review
2017
Review
2017
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
Review
2015
Review
2015
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian…
Review
2015
Review
2015
Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer
2015
2015
Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America
The open‐label, single‐arm enzalutamide expanded access program (EAP) in the United States and Canada evaluated the safety of… 
Review
2014
Review
2014
Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Review
2012
Review
2012
Sipuleucel‐T (Provenge®) for castration‐resistant prostate cancer
What's known on the subject? and What does the study add? 
Review
2012
Review
2012
Urologists and oncologists: adapting to a new treatment paradigm in castration‐resistant prostate cancer (CRPC)
What's known on the subject? and What does the study add? 
Review
2012
Review
2012
Future perspectives of prostate cancer therapy
We summarize several recent laboratory advances to tackle the problem of tumor-stroma-immune cell microenvironment interaction… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)